Print |
  • Text A A
  • PDxDNA_PInkOBGYN_WomensHealthV2.jpg

    HYPOTHETICAL DOCTOR VISIT

    Following is a situation faced by primary care physicians and gynecologists seeing female patients with blood in their urine

    Hypothetical Scenario

    A patient presents with hematuria (blood in the urine). The gynecologist or primary care physician performs a standard gynecological workup that indicates the patient’s hematuria is not attributable to infection. 

    Next Step*

    Noting that the patient has risk factors for bladder cancer, the gynecologist or primary care physician sends the patient’s urine sample to a service laboratory to perform a molecular test that can be used as an aid in the early detection of bladder cancer. 

    *This is one diagnostic option.

    Benefit

    The molecular test result comes back typically within 72 hours, providing answers the gynecologist or primary care physician can use to support the patient’s health care management.

    UroVysion Bladder Cancer Kit Results

     

    Normal-Cell.jpg

     

    UroVysion Clinician Benefits

    • Detects chromosomal abnormalities associated with the development and recurrence of bladder cancer.
    • Delivers positive/negative results in suspicious cystoscopy or atypical cytology cases.
    • Shows 100% sensitivity among the most severe tumors (T2 and Tis).
    • Performs without interference in the presence of substances such as BCG, Mytomycin C, and Thiotepa in urine samples.

    Intended Use: The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

    Warnings and Limitations

    1. The UroVysion Kit has been optimized for identifying and quantitating chromosomes 3, 7, and 17, and locus 9p21 in human urine specimens.
    2. The performance of the UroVysion Kit was validated using the procedures provided in the package insert only. Modifications to these procedures may alter the performance of the assay.
    3. The clinical interpretation of any test results should be evaluated within the context of the patient’s medical history and other diagnostic laboratory test results.
    4. UroVysion assay results may not be informative if the specimen quality and/or specimen slide preparation is inadequate, e.g., the presence of excessive granulocytes or massive bacteruria.
    5. Technologists performing the UroVysion signal enumeration must be capable of visually distinguishing between the red and green signals.
    6. Positive UroVysion results in the absence of other signs or symptoms of bladder cancer recurrence may be evidence of other urinary tract related cancers—e.g., ureter, urethra, renal, and/or (in males) prostate—and further patient follow-up is justified. In a study conducted on patients with hematuria, 3 patients whose initial bladder cystoscopy was negative, were subsequently diagnosed with renal cancer within 6 months of this initial study visit. All 3 of these cases tested positive by UroVysion.
    7. If UroVysion results are negative, but standard clinical or diagnostic tests (e.g., cytology, cystoscopy) are positive, the standard procedures take precedence over the UroVysion test. Although the UroVysion Kit was designed to detect genetic changes associated with most bladder cancers, there will be some bladder cancers whose genetic changes cannot be detected by the UroVysion test.
    8. Stage Ta solitary tumors smaller than 5mm could not be detected by UroVysion FISH. UroVysion FISH results are dependent on the amount of tumor cells that are deposited on the slide.

     

    Caution: United States Federal law restricts this device to sale and distribution to, or on the order of, a physician or a clinical laboratory; use is restricted to, by, or on the order of a physician.

     

    FOR IN VITRO DIAGNOSTIC USE ONLY